Powered by

Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020; -- People Living With HIV Switching to Biktarvy from Boosted PI-Based Regimens Achieved Sustained Viral Suppression up to 156 Weeks --; -- O

Oct 05, 2020 - Business Wire

Gilead Sciences, Inc. (Nasdaq: GLD) today announced long-term study results, which showed that people living with HIV who switched to the once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) from a boosted protease inhibitor-based regimen consisting of atazanavir (ATV) or darunavir (DRV) plus either emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) or abacavir (ABC)/lamivudine (3TC) maintained virologic suppress...